Table 9 Data at randomization for simulation 2C
From: Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials
Placebo | Treatment | ASD | |
|---|---|---|---|
n = 3000 | n = 3000 | ||
Age (years) | 68.0 (±9.8) | 67.8 (±10.1) | 0.03 |
Black race | |||
No | 2,096 (69.9%) | 2,089 (69.6%) | 0.01 |
Yes | 904 (30.1%) | 911 (30.4%) | 0.01 |
Systolic blood pressure (mm Hg) | 140.0 (±15.1) | 139.2 (±14.9) | 0.05 |
Diastolic blood pressure (mm Hg) | 78.4 (±12.0) | 77.4 (±11.9) | 0.08 |
Serum creatinine (mg/dl) | 1.1 (±0.3) | 1.1 (±0.3) | 0.01 |
eGFR (ml min–1 1.73 m–2) | 71.7 (±19.6) | 72.2 (±20.2) | 0.02 |
Statin use | |||
No | 1,692 (56.4%) | 1,678 (55.9%) | 0.01 |
Yes | 1,308 (43.6%) | 1,322 (44.1%) | 0.01 |
Aspirin use | |||
No | 1,518 (50.6%) | 1,467 (48.9%) | 0.03 |
Yes | 1,482 (49.4%) | 1,533 (51.1%) | 0.03 |
Framingham risk score | 24.7 (±11.9) | 25.1 (±11.6) | 0.04 |
Smoking status | |||
Never | 1,334 (44.5%) | 1,312 (43.7%) | 0.01 |
Former | 1,254 (41.8%) | 1,256 (41.9%) | 0 |
Current | 412 (13.7%) | 432 (14.4%) | 0.02 |